Literature DB >> 24552454

GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans.

Sharmila C Subaran1, Matthew A Sauder1, Weidong Chai1, Linda A Jahn1, Dale E Fowler2, Kevin W Aylor1, Ananda Basu3, Zhenqi Liu1.   

Abstract

Muscle microvascular surface area determines substrate and hormonal exchanges between plasma and muscle interstitium. GLP-1 (glucagon-like peptide-1) regulates glucose-dependent insulin secretion and has numerous extrapancreatic effects, including a salutary vascular action. To examine whether GLP-1 recruits skeletal and cardiac muscle microvasculature in healthy humans, 26 overnight-fasted healthy adults received a systemic infusion of GLP-1 (1.2 pmol/kg of body mass per min) for 150 min. Skeletal and cardiac muscle MBV (microvascular blood volume), MFV (microvascular flow velocity) and MBF (microvascular blood flow) were determined at baseline and after 30 and 150 min. Brachial artery diameter and mean flow velocity were measured and total blood flow was calculated before and at the end of the GLP-1 infusion. GLP-1 infusion raised plasma GLP-1 concentrations to the postprandial levels and suppressed plasma glucagon concentrations with a transient increase in plasma insulin concentrations. Skeletal and cardiac muscle MBV and MBF increased significantly at both 30 and 150 min (P<0.05). MFV did not change in skeletal muscle, but decreased slightly in cardiac muscle. GLP-1 infusion significantly increased brachial artery diameter (P<0.005) and flow velocity (P=0.05) at 150 min, resulting in a significant increase in total brachial artery blood flow (P<0.005). We conclude that acute GLP-1 infusion significantly recruits skeletal and cardiac muscle microvasculature in addition to relaxing the conduit artery in healthy humans. This could contribute to increased tissue oxygen, nutrient and insulin delivery and exchange and therefore better prandial glycaemic control and tissue function in humans.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24552454      PMCID: PMC4353574          DOI: 10.1042/CS20130708

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  44 in total

1.  Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor.

Authors:  O Erdogdu; D Nathanson; A Sjöholm; T Nyström; Q Zhang
Journal:  Mol Cell Endocrinol       Date:  2010-05-07       Impact factor: 4.102

2.  Insulin-induced microvascular recruitment in skin and muscle are related and both are associated with whole-body glucose uptake.

Authors:  Rick I Meijer; Michiel P De Boer; Martine R Groen; Etto C Eringa; Stephen Rattigan; Eugene J Barrett; Yvo M Smulders; Erik H Serne
Journal:  Microcirculation       Date:  2012-08       Impact factor: 2.628

Review 3.  Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature.

Authors:  Eugene J Barrett; Hong Wang; Charles T Upchurch; Zhenqi Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-05-24       Impact factor: 4.310

4.  Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.

Authors:  D Nathanson; B Ullman; U Löfström; A Hedman; M Frick; A Sjöholm; T Nyström
Journal:  Diabetologia       Date:  2012-01-13       Impact factor: 10.122

5.  Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow.

Authors:  Steven P Moberly; Zachary C Berwick; Meredith Kohr; Mark Svendsen; Kieren J Mather; Johnathan D Tune
Journal:  Exp Biol Med (Maywood)       Date:  2012-02-16

6.  Candesartan acutely recruits skeletal and cardiac muscle microvasculature in healthy humans.

Authors:  Matthew A Sauder; Jia Liu; Linda A Jahn; Dale E Fowler; Weidong Chai; Zhenqi Liu
Journal:  J Clin Endocrinol Metab       Date:  2012-04-16       Impact factor: 5.958

7.  Defects in GLP-1 response to an oral challenge do not play a significant role in the pathogenesis of prediabetes.

Authors:  Galina Smushkin; Airani Sathananthan; Chiara Dalla Man; Alan R Zinsmeister; Michael Camilleri; Claudio Cobelli; Robert A Rizza; Adrian Vella
Journal:  J Clin Endocrinol Metab       Date:  2011-11-16       Impact factor: 5.958

8.  Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure.

Authors:  Mads Halbirk; Helene Nørrelund; Niels Møller; Jens Juul Holst; Ole Schmitz; Roni Nielsen; Jens Erik Nielsen-Kudsk; Søren Steen Nielsen; Torsten Toftegaard Nielsen; Hans Eiskjaer; Hans Erik Bøtker; Henrik Wiggers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-15       Impact factor: 4.733

9.  Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism.

Authors:  Weidong Chai; Zhenhua Dong; Nasui Wang; Wenhui Wang; Lijian Tao; Wenhong Cao; Zhenqi Liu
Journal:  Diabetes       Date:  2012-02-22       Impact factor: 9.461

10.  Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans.

Authors:  Weidong Chai; Jia Liu; Linda A Jahn; Dale E Fowler; Eugene J Barrett; Zhenqi Liu
Journal:  Diabetes Care       Date:  2011-05-26       Impact factor: 19.112

View more
  34 in total

1.  Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study.

Authors:  Roni Nielsen; Anders Jorsal; Peter Iversen; Lars Poulsen Tolbod; Kirsten Bouchelouche; Jens Sørensen; Hendrik Johannes Harms; Allan Flyvbjerg; Lise Tarnow; Caroline Kistorp; Ida Gustafsson; Hans Erik Bøtker; Henrik Wiggers
Journal:  J Nucl Cardiol       Date:  2017-08-02       Impact factor: 5.952

Review 2.  Muscle microvasculature's structural and functional specializations facilitate muscle metabolism.

Authors:  Yvo H A M Kusters; Eugene J Barrett
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-12-29       Impact factor: 4.310

3.  Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats.

Authors:  Weidong Chai; Zhuo Fu; Kevin W Aylor; Eugene J Barrett; Zhenqi Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-07-19       Impact factor: 4.310

Review 4.  Potential of Glucagon-Like Peptide 1 as a Regulator of Impaired Cholesterol Metabolism in the Brain.

Authors:  Young-Kook Kim; Juhyun Song
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

5.  GLP-1 Receptor Expression Within the Human Heart.

Authors:  Laurie L Baggio; Bernardo Yusta; Erin E Mulvihill; Xiemin Cao; Catherine J Streutker; Jagdish Butany; Thomas P Cappola; Kenneth B Margulies; Daniel J Drucker
Journal:  Endocrinology       Date:  2018-04-01       Impact factor: 4.736

6.  Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance.

Authors:  Nasui Wang; Alvin W K Tan; Linda A Jahn; Lee Hartline; James T Patrie; Shaoda Lin; Eugene J Barrett; Kevin W Aylor; Zhenqi Liu
Journal:  Diabetes Care       Date:  2019-12-30       Impact factor: 19.112

Review 7.  Adiponectin and insulin cross talk: the microvascular connection.

Authors:  Lina Zhao; Zhuo Fu; Zhenqi Liu
Journal:  Trends Cardiovasc Med       Date:  2014-08-07       Impact factor: 6.677

8.  Feeding critically ill patients the right 'whey': thinking outside of the box. A personal view.

Authors:  Paul E Marik
Journal:  Ann Intensive Care       Date:  2015-05-28       Impact factor: 6.925

Review 9.  Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease.

Authors:  William B Horton; Eugene J Barrett
Journal:  Endocr Rev       Date:  2021-01-28       Impact factor: 19.871

10.  Insulin-mediated muscle microvascular perfusion and its phenotypic predictors in humans.

Authors:  Kaitlin M Love; Linda A Jahn; Lee M Hartline; James T Patrie; Eugene J Barrett; Zhenqi Liu
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.